YHYubei Huang

Yubei Huang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yubei Huang has a total of 100 co-authors. Here are the top co-authors by number of shared publications:

  • Lei Yang

    15 shared publications
  • Fengju Song

    13 shared publications
  • Zhangyan Lyu

    Department of Epidemiology and Biostatistics, Key Laboratory of Molecular Cancer Epidemiology, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, China

    13 shared publications
  • Xiaomin Liu

    12 shared publications
  • Chao Sheng

    Department of Epidemiology and Biostatistics, Key Laboratory of Molecular Cancer Epidemiology, Key Laboratory of Prevention and Control of Human Major Diseases, Ministry of Education, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin 300060, China

    11 shared publications
  • Yunmeng Zhang

    11 shared publications

Latest Publications

  • Open Access

    Global cancer in 2024 vs. 2022: current estimates, temporal trends, future projections, and associated factors

    by Ximin Gao, Wenlong Zheng, Weiping Wang, Qian Zhu, Yue Ma, Weiqin Li, Shengbo Xia, Xiaomin Liu, Yunmeng Zhang, Kexin Chen, et al.

  • Open Access

    Burden, trends, and projections of prostate cancer: global cancer statistics (GLOBOCAN) estimates for 2024 and 2022

    by Xiaomin Liu, Wenlong Zheng, Yuting Ji, Jingjing Li, Yunmeng Zhang, Kexin Chen, Fengju Song, Lei Yang, Yubei Huang

  • Open Access

    Joint impacts of genetic and non-genetic risk scores on risks of different subtypes of breast cancer among Chinese females

    by Zhipeng Wang, Yunmeng Zhang, Huan Wang, Zhangyan Lyu, Hongji Dai, Yanrui Zhao, Peifang Liu, Ying Zhu, Fangfang Song, Yubei Huang, et al.

    Purpose: To investigate the joint impacts of genetic and non-genetic factors on breast cancer (BC) subtypes among Chinese females, and to investigate the performance of optimized subtype-specific polygenic risk scores (PRS) with less single nucleotide polymorphisms (SNPs). Methods: A total of 6,916 BC cases and 5,653 controls were used to assess the independent and joint impacts of PRS and non-genetic established risk score (ERS) on risks of overall and subtype-specific BC. The PRS were optimized by excluding low-penetrance SNPs until comparable area under receiver-operator-curve (AUCs) achieved. Results: For the preliminary PRS with 21 Chinese BC-specific SNPs, the odds ratio (OR) of overall BC for the top decile compared to bottom decile (top-to-bottom decile) of PRS was 4.21 (95%CI: 3.47–5.10), and the OR per decile of PRS was 1.15 (95% CI: 1.13–1.16). For luminal A, luminal B, HER-2 enriched, and basal-like BC, the ORs for top-to-bottom decile were 4.58, 4.37, 3.08 and 2.90, respectively. After integrating four BC subtypes into two subtypes, relatively higher OR for top-to-bottom decile was observed for luminal BC than non-luminal BC (4.54 vs. 3.02), and a similar trend was for OR per decile (1.15 vs. 1.11). The optimized 13-SNP-PRS can achieve comparable performance of 21-SNP-PRS for luminal BC. After incorporating PRS into risk prediction of luminal BC, the AUC increased from 0.673 to 0.697, and the joint OR of PRS and ERS was 12.46(95%CI: 9.38–16.56). Similar performances of PRS were validated in UK biobank. Conclusion: PRS can well identify Chinese women at high-risk of BC, especially for luminal BC, and should be incorporated into risk-stratified BC intervention.

  • Open Access

    Global landscape of early-onset thyroid cancer: current burden, temporal trend and future projections on the basis of GLOBOCAN 2022

    by Qianyun Jin, Jie Wu, Caiyun Huang, Jingjing Li, Yunmeng Zhang, Yuting Ji, Xiaomin Liu, Hongyuan Duan, Zhuowei Feng, Ya Liu, et al.

    With rapid social-economic development and widespread screening, the surge in incidence and overdiagnosis of thyroid cancer is more worrying among the young than the general population. This problem, however, still lacks adequate attention. We retrieved the original data of current, past and future burden of thyroid cancer from the Global Cancer Observatory (GLOBOCAN) 2022. We calculated the age-specific mortality-to-incidence ratio (MIR) by dividing age-specific mortality rates by incidence rates to quantify potential overdiagnosis, and used Segi's world standard population to calculate the age-standardised incidence rate (ASIR) and age-standardised mortality rate (ASMR). We then assessed the correlation between the human development index (HDI) and ASIR/ASMR using the linear correlation coefficient (r). Lastly, we characterised the temporal trend with the estimated annual percentage change (EAPC) and project the early-onset thyroid cancer burdens to 2050. Globally, there were an estimated 239 362 (ASIR = 4.00 per 100 000 population) cases and 2409 (ASMR = 0.04 per 100 000 population) deaths from thyroid cancer among individuals aged <40 years in 2022. Compared to its ranking as the 7th most common cancer in the overall population, thyroid cancer rose to become the 2nd most common cancer among individuals <40 years. Nearly 99% of thyroid cancer cases in individuals 80 years (MIR = 0.66) were overdiagnosed. The ASIR of early-onset thyroid cancer varied widely (from 0.13 to 13.17 per 100 000 population), while the ASMR remains relatively similar and low across different regions. The ASIR of early-onset thyroid cancer increased with HDI (r = 0.69), while the ASMR decreased (r = -0.22). The ASIR of early-onset thyroid cancer had the fastest upward trend (EAPC in males vs. females: 9.88 vs. 9.28%) compared to early-onset cancers at other sites, while ASMR showed a downward trend (EAPC in males vs. females: -0.38% vs. -1.33%). The Republic of Korea experienced the highest EAPC for early-onset thyroid cancer ASIR (males vs. females: 29.95% vs. 23.04%). If national rates from 2022 remain stable, projected cases of early-onset thyroid cancer would decrease in high (-13.3%) and very high (-10.9%) HDI countries, but increase in low (96.5%) and medium HDI countries (11.7%). The trend of early-onset thyroid cancer at the global level is more alarming than that of thyroid cancer overall. The younger age at diagnosis of thyroid cancer, the higher risk of potential overdiagnosis. Without timely interventions, the thyroid cancer burden will inevitably become a serious global public health issue, especially for the young population.


  • Top Cited Papers
    Open Access

    The epidemiological landscape of lung cancer: current status, temporal trend and future projections based on the latest estimates from GLOBOCAN 2022

    by Yuting Ji, Yunmeng Zhang, Siwen Liu, Jingjing Li, Qianyun Jin, Jie Wu, Hongyuan Duan, Xiaomin Liu, Lei Yang, Yubei Huang


  • Top Cited Papers
    Open Access

    Global burden of female breast cancer: new estimates in 2022, temporal trend and future projections up to 2050 based on the latest release from GLOBOCAN

    by Yunmeng Zhang, Yuting Ji, Siwen Liu, Jingjing Li, Jie Wu, Qianyun Jin, Xiaomin Liu, Hongyuan Duan, Zhuowei Feng, Ya Liu, et al.


  • Top Cited Papers
    Open Access

    Global burden of cervical cancer: current estimates, temporal trend and future projections based on the GLOBOCAN 2022

    by Jie Wu, Qianyun Jin, Yunmeng Zhang, Yuting Ji, Jingjing Li, Xiaomin Liu, Hongyuan Duan, Zhuowei Feng, Ya Liu, Yacong Zhang, et al.


  • Open Access

    Decreased risk of cardiovascular disease mortality associated with occasional positive screens following cancer screenings

    by Yuting Ji, Yu Zhang, Hongyuan Duan, Xiaomin Liu, Yunmeng Zhang, Zhuowei Feng, Jingjing Li, Zeyu Fan, Ya Liu, Yacong Zhang, et al.

    Positive results from cancer screenings, like a cancer diagnosis, can increase the risk of cardiovascular disease (CVD) mortality due to heightened psychological stress. However, positive screening results may also serve as a teachable moment to encourage the adoption of a healthier lifestyle. Consequently, the overall association between positive screenings and CVD mortality risk remains unclear. Based on PLCO data, the risk of CVD mortality associated with the number and types of positive screens was evaluated using Cox regression models among 149,258 eligible participants enrolled between 1993 and 2001. Additional analyses explored these associations stratified by prior CVD history. Exploratory analyses were also conducted to investigate whether positive screens were linked to the potential adoption of a healthier lifestyle. After a median follow-up of 19 years, significantly decreased risk of CVD mortality was observed for individuals with occasional positive screening (≤ 2 positive screens) [adjusted hazard ratio (HR, 95%CIs): 0.931 (0.897–0.968), P < 0.001] compared to the control arm. This effect was particularly notable for flexible sigmoidoscopy [0.842 (0.802–0.884), P < 0.001] and transvaginal ultrasound [0.855 (0.776–0.942), P = 0.002]. However, when the number of positive screens increased to more than two, the reduced risk of CVD mortality became non-significant [0.977 (0.941–1.014), P = 0.220]. Subgroup analyses revealed a greater reduction in CVD mortality risk among participants without a history of CVD [0.917 (0.864–0.973)] compared to those with a history of CVD [0.944 (0.898–0.993)]. Sensitivity analyses excluding screening-detected cancers showed similar association in the overall population [0.933 (0.897–0.970)], as well as in both subgroups with [0.945 (0.898–0.995)] and without previous CVD [0.919 (0.865–0.976)]. Exploratory analyses indicated a significantly higher proportion of any body mass index (BMI) reduction among those with a baseline BMI ≥ 25 kg/m2 who had positive screens compared to the control arm, particularly for individuals with occasional positive screens (48.07% vs. 47.04%, P value = 0.037). Occasional positive cancer screening are associated with reduced risk of CVD mortality, regardless of prior CVD history, cancer diagnosis, and other competitive risks.


  • Open Access

    Severe obesity, high inflammation, insulin resistance with risks of all-cause mortality and all-site cancers, and potential modification by healthy lifestyles

    by Qianyun Jin, Siwen Liu, Yunmeng Zhang, Yuting Ji, Jie Wu, Hongyuan Duan, Xiaomin Liu, Jingjing Li, Yacong Zhang, Zhangyan Lyu, et al.

    Severe obesity is often associated with inflammation and insulin resistance (IR), which expected to increase the risks of mortality and cancers. However, this relationship remains controversial, and it’s unclear whether healthy lifestyles can mitigate these risks. The independent and joint associations of severe obesity (body mass index ≥ 35 m/kg2), inflammation (C-reactive protein > 10 mg/L and systemic inflammation markers > 9th decile), and IR surrogates with the risks of all-cause mortality and all-site cancers, were evaluated in 163,008 participants from the UK Biobank cohort. Further analyses were conducted to investigate how these associations were modified by lifestyle. During a median follow-up of 11.0 years, we identified 8844 deaths and 20,944 cancer cases. Severe obesity, inflammation and IR were each independently associated with increased risks of all-cause mortality [HRs(95%CIs) 1.24(1.17–1.30), 1.63(1.55–1.72) and 1.11(1.05–1.17)] and all-site cancers [1.06(1.02–1.10), 1.14(1.10–1.19) and 1.02(0.99–1.06)]. Joint analyses revealed significantly elevated risks of all-cause mortality and all-site cancers due to interaction between severe obesity, inflammation and IR, with the highest HRs(95%CIs) of 1.88(1.67–2.11) and 1.20(1.08–1.34), respectively. Further analyses showed stronger interaction between severe obesity, inflammation, IR and lifestyles, with similar associations observed in both males and females. Additionally, compared with unfavorable lifestyles, favorable lifestyles attenuated the risks of both all-cause mortality [the highest HRs(95%CIs) 2.35(1.75–3.15) vs. 3.72(2.86–4.84) for favorable vs. unfavorable lifestyles] and all-site cancers [1.16(0.89–1.53) vs. 1.63(1.26–2.10)]. Severe obesity interacts with inflammation and IR to exacerbate the risks of all-cause mortality and all-site cancers. Nonetheless, adherence to healthy lifestyles is recommended to mitigate these increased risks.


  • Open Access

    Risk factors and prediction model of breast cancer-related lymphoedema in a Chinese cancer centre: a prospective cohort study protocol

    by Aomei Shen, Jingming Ye, Hongmei Zhao, Wanmin Qiang, Hongmeng Zhao, Yubei Huang, Yujie Zhou, Yue Wang, Xin Li, Zhongning Zhang, et al.

    Introduction Lymphoedema is a distressing and long-term complication for breast cancer survivors. However, the reported incidence of lymphoedema varies, and its risk factors remain underexplored. Currently, a well-established risk prediction model is still lacking. This study aims to describe the rationale, objectives, protocol and baseline characteristics of a prospective cohort study focused on examining the incidence and risk factors of breast cancer-related lymphoedema (BCRL), as well as developing a risk prediction model. Methods and analysis This study is an ongoing single-centre prospective observational cohort study recruiting 1967 patients with breast cancer scheduled for surgery treatment in northern China between 15 February 2022 and 21 June 2023. Assessments will be conducted presurgery and at 1, 3, 6, 12, 18, 24, 30 and 36 months postsurgery. Bilateral limb circumferences will be measured by patients at home or by researchers at the outpatient clinics during follow-up visits. The diagnosis of lymphoedema is based on a relative limb volume increase of ≥10% from the preoperative assessment. Self-reported symptoms will be assessed to assist in diagnosis. Potential risk factors are classified into innate personal traits, behavioural lifestyle, interpersonal networks, socioeconomic status and macroenvironmental factors, based on health ecology model. Data collection, storage and management were conducted using the online ‘H6WORLD’ data management platform. Survival analysis using the Kaplan-Meier estimate will determine the incidence of BCRL. Risk factors of BCRL will be analysed using log-rank test and COX-LASSO regression. Traditional COX regression analysis and seven common survival analysis machine learning algorithms (COX, CARST, RSF, GBSM, XGBS, SSVM and SANN) will be employed for model construction and validation. Ethics and dissemination The study protocol was approved by the Biomedical Ethics Committee of Peking University (IRB00001052-21124) and the Research Ethics Committee of Tianjin Medical University Cancer Institute and Hospital (bc2023013). The results of this study will be published in peer-reviewed journals and will be presented at several research conferences. Trial registration number ChiCTR2200057083.